-
-
-
-
-
-
-
scPharmaceuticals (SCPH) Announces Filing Acceptance of sNDA Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
-
-
-
-
-
-
-
scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration
-
-
-
-
-
-
-
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

